drugset / Trial / NCT00957203
Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
NaSingle-groupOpen-labelTreatment
Summary
Patients with Parkinson's disease who completed the prior double-blind study 6002-009 are eligible to enter into this long-term study. The purpose of this study is to evaluate the safety and efficacy of KW-6002 administered long-term in patients with advanced Parkinson's disease treated with levodopa.
Timeline
- Start
- 2009-10
- Primary completion
- 2011-09
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Istradefylline | Small molecule | 20 mg | Oral |
| Subject | Istradefylline | Small molecule | 40 mg | Oral |